SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) announced today an agreement with Amgen for the purchase and installation of a large, multi-component genetic analysis system for Infinium® genotyping. Amgen, in collaboration with the Brigham & Women’s Hospital will use Illumina technology to analyze approximately 28,000 samples at Amgen’s facility in Cambridge, Massachusetts as part of the Women’s Genome Health Study. The study will look at genetic variation in American women that may underlie a range of serious illness such as heart disease, stroke, diabetes, breast cancer and osteoporosis.
